Intersect ENT, Inc. Provided earnings guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company’s expected revenue to be in the range of $29.3 to $29.5 million, an increase of 21-22% compared to $24.2 million for the fourth quarter of 2016. For the full year, the company’s expected revenue to be in the range of $96.1 to $96.3 million, an increase of 22% compared to $78.7 million for 2016. The company forecasts full year 2018 revenue in the range of $111 to $116 million, which would represent an increase of 15%-20% over 2017 and which includes an estimated 8% contribution from SINUVA product sales. The company forecasts for first quarter 2018 revenue is in the range of $23.2 to $23.7 million, and the company continues to expect to launch SINUVA commercially in the second quarter of 2018.